BioTime CEO Dr. Michael West to Present at the 2012 Agora Financial Investment Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 16, 2012--
BioTime, Inc. (NYSE MKT:BTX) announced today that Chief Executive
Officer Michael D. West, Ph.D. will present at the 2012 Agora Financial
Investment Symposium on Tuesday, July 24, 2012, 4:40 p.m. PDT, at the
Fairmont Hotel in Vancouver, British Columbia, Canada. Dr. West will
speak on “The Stem Cell Revolution: Designing First-in-Class Therapies
for Age-Related Degenerative Disease,” including an update on product
development programs at BioTime and its subsidiaries. Dr. West’s
presentation will be available online at www.biotimeinc.com.
The annual symposium held July 24-27 will be the thirteenth for Agora
Financial, LLC, an independent firm providing economic forecasting and
financial research for over twenty-five years.
The Company also announced that the corporate presentation given by Dr.
West at the BioTime Annual Meeting of Shareholders held at the Harvard
Club of New York City on June 26, 2012 is now available for viewing on
BioTime's website under the BioTime
2012 Annual Shareholder Meeting link on the homepage at www.biotimeinc.com.
The annual corporate presentation provides an update on the technology
and business activities of BioTime and its subsidiaries.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of applications. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine, including a wide array of proprietary ACTCellerate™
cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly
known as HyStem®-Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary,
LifeMap Sciences, Inc., markets GeneCards®: the
leading human gene database, and is developing an integrated database
suite to complement GeneCards® that will also include
the LifeMap™ database of embryonic development, stem cell
research and regenerative medicine, and MalaCards, the human
disease database. LifeMap will also market BioTime research products.
BioTime's lead product, Hextend®, is a blood plasma volume
expander manufactured and distributed in the U.S. by Hospira, Inc. and
in South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements. Additional information about BioTime can be found on the web
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
Source: BioTime, Inc.
Peter Garcia, 510-521-3390 ext. 367
Segall, 510-521-3390 ext. 301